Hybio Pharmaceutical

Hybio Pharmaceutical Co., Ltd. is a national high-tech enterprise specializing in the research, production, and sales of peptide drugs, always focusing on the fields of peptide drugs and small nucleic acids. The company was listed on the Shenzhen Stock Exchange in 2011 (stock code: 300199) and is one of the earliest peptide drug companies to be listed in China. The company has built a national and local joint engineering laboratory for polypeptide drugs, a national public experimental center for polypeptide innovative drugs, and a national pilot test technology platform for polypeptide drug preparation. It has undertaken a number of national subjects and won the second prize of the the State Technological Innovation Award, the Chinese Patent Excellence Award, the National Intellectual Property Demonstration Enterprise, the Guangdong Science and Technology Award, the Shenzhen Mayor Award and other national, provincial and municipal honorary awards. Up to now, it has passed GMP certifications in China, the United States, the European Union, Brazil, Australia, South Korea, and other countries, connecting the vertical industrial chains of upstream, midstream, and downstream, ensuring full chain control from raw materials to drugs. Hybio Pharmaceutical has always adhered to the vision of continuous innovation and becoming a leader in the peptide industry, with the eternal mission of safeguarding life and health. The company adheres to the industrial chain layout around the three strategic pillars of "talent, innovation and imitation, and internationalization", and adopts a dual wheel drive model of "self-developed+internal and external resource integration" to create a competitive "innovative drug+generic drug" product pipeline, pilot emerging industries such as beauty peptides, explore various application scenarios in the peptide field, achieve diversified operations under the product leadership strategy, and promote the sustained, stable, rapid, healthy, and efficient development of the company.